Literature DB >> 25814381

Risk Factors Associated with HCV Among Opioid-Dependent Patients in a Multisite Study.

M Schulte1, Y Hser, A Saxon, E Evans, L Li, D Huang, M Hillhouse, C Thomas, W Ling.   

Abstract

We examined risk factors associated with hepatitis C virus (HCV) infection among opioid-dependent patients enrolled into medication-assisted therapy (buprenorphine or methadone) to determine factors affecting chronic infection. Patients (N = 1039) were randomized as part of a larger, multisite clinical trial sponsored by the National Drug Abuse Treatment Clinical Trials Network assessing liver function. HCV status was first assessed with an antibody screen; if positive, then current infection was determined with an antigen screen testing for detectable virus. Patients were classified as HCV negative, HCV positive but have cleared the virus, or as having chronic HCV. Logistic regression analysis was used to examine demographic and behavioral correlates of the three groups. Thirty-four percent of patients were classified with chronic infection and 14% had evidence of prior infection with apparent clearing of the virus. Chronic infection was associated with recent injection drug use and cocaine use. Chronic HCV infection was also associated with being older and Hispanic. Age, ethnicity, and current drug use increase the likelihood of being chronically infected with HCV. Strategies targeting high risk subgroups can aid in preventing further disease escalation.

Entities:  

Mesh:

Year:  2015        PMID: 25814381      PMCID: PMC4558248          DOI: 10.1007/s10900-015-0016-2

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  36 in total

Review 1.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

2.  The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users.

Authors:  Julie Bruneau; Elise Roy; Nelson Arruda; Geng Zang; Didier Jutras-Aswad
Journal:  Addiction       Date:  2012-03-22       Impact factor: 6.526

3.  Referral for chronic hepatitis C treatment from a drug dependency treatment setting.

Authors:  Richard Hallinan; Andrew Byrne; Kingsley Agho; Gregory J Dore
Journal:  Drug Alcohol Depend       Date:  2006-10-25       Impact factor: 4.492

Review 4.  Hepatitis C virus infection in USA: an estimate of true prevalence.

Authors:  Eric Chak; Andrew H Talal; Kenneth E Sherman; Eugene R Schiff; Sammy Saab
Journal:  Liver Int       Date:  2011-03-16       Impact factor: 5.828

5.  Detection of hepatitis C core antigen in serum or plasma as a marker of hepatitis C viraemia in the serological window-phase.

Authors:  A Widell; V Molnegren; F Pieksma; M Calmann; J Peterson; S R Lee
Journal:  Transfus Med       Date:  2002-04       Impact factor: 2.019

6.  HCV infection prevalence lower than expected among 18-40-year-old injection drug users in San Diego, CA.

Authors:  Richard S Garfein; Amanda Rondinelli; Richard F W Barnes; Jazmine Cuevas; Mitcheal Metzner; Michele Velasquez; David Rodriguez; Meredith Reilly; Jian Xing; Eyasu H Teshale
Journal:  J Urban Health       Date:  2013-06       Impact factor: 3.671

Review 7.  Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients.

Authors:  David M Novick; Mary Jeanne Kreek
Journal:  Addiction       Date:  2008-04-16       Impact factor: 6.526

8.  Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004.

Authors:  Joseph J Amon; Richard S Garfein; Linda Ahdieh-Grant; Gregory L Armstrong; Lawrence J Ouellet; Mary H Latka; David Vlahov; Steffanie A Strathdee; Sharon M Hudson; Peter Kerndt; Don Des Jarlais; Ian T Williams
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

9.  Hepatitis C infection in non-treatment-seeking heroin users: the burden of cocaine injection.

Authors:  P Roux; L Fugon; J D Jones; S D Comer
Journal:  Am J Addict       Date:  2013-06-06

10.  Testing for HCV infection: an update of guidance for clinicians and laboratorians.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-05-10       Impact factor: 17.586

View more
  6 in total

1.  A systematic scoping review of research on Black participants in the National Drug Abuse Treatment Clinical Trials Network.

Authors:  LaTrice Montgomery; Ann Kathleen Burlew; Angela M Haeny; Chizara A Jones
Journal:  Psychol Addict Behav       Date:  2019-06-27

Review 2.  Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

Authors:  Suzanne Nielsen; Wai Chung Tse; Briony Larance
Journal:  Cochrane Database Syst Rev       Date:  2022-09-05

3.  Severe bacterial infections in people who inject drugs: the role of injection-related tissue damage.

Authors:  Alexander Hrycko; Pedro Mateu-Gelabert; Courtney Ciervo; Rebecca Linn-Walton; Benjamin Eckhardt
Journal:  Harm Reduct J       Date:  2022-05-02

4.  Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention.

Authors:  Benjamin Eckhardt; Emily R Winkelstein; Marla A Shu; Michael R Carden; Courtney McKnight; Don C Des Jarlais; Marshall J Glesby; Kristen Marks; Brian R Edlin
Journal:  PLoS One       Date:  2017-05-19       Impact factor: 3.240

Review 5.  Hispanic participants in the National Institute on Drug Abuse's Clinical Trials Network: A scoping review of two decades of research.

Authors:  Brittany H Eghaneyan; Katherine Sanchez; Angela M Haeny; LaTrice Montgomery; Teresa Lopez-Castro; A Kathleen Burlew; Afsaneh Rezaeizadeh; Michael O Killian
Journal:  Addict Behav Rep       Date:  2020-06-01

6.  Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder.

Authors:  Alice Fiddian-Green; Aline Gubrium; Calla Harrington; Elizabeth A Evans
Journal:  Int J Environ Res Public Health       Date:  2022-07-30       Impact factor: 4.614

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.